Ajax loader
By using our website, you agree to our use of cookies as described in Cookie Policy.

Can't find what you're looking for?

 

Be sure to Sign in to see all available content.

 

If you don't have an account, Register here.

Search results for: Pharmacologist

GLOBAL-PHARMACEUTICAL/
RTS1UINL
June 30, 2018
Used blister packets that contained medicines, tablets and pills are seen, in this picture illustration...
London, United Kingdom
Used blister packets that contained medicines, tablets and pills are seen, in this picture illustration...
Used blister packets that contained medicines, tablets and pills are seen, in this picture illustration taken June 30, 2018. REUTERS/Russell Boyce/Illustration
GLOBAL-PHARMACEUTICAL/
RTS1UINK
June 30, 2018
Used blister packets that contained medicines, tablets and pills are seen, in this picture illustration...
London, United Kingdom
Used blister packets that contained medicines, tablets and pills are seen, in this picture illustration...
Used blister packets that contained medicines, tablets and pills are seen, in this picture illustration taken June 30, 2018. REUTERS/Russell Boyce/Illustration
GLOBAL-PHARMACEUTICAL/
RTS1UINJ
June 30, 2018
Used blister packets that contained medicines, tablets and pills are seen, in this picture illustration...
London, United Kingdom
Used blister packets that contained medicines, tablets and pills are seen, in this picture illustration...
Used blister packets that contained medicines, tablets and pills are seen, in this picture illustration taken June 30, 2018. REUTERS/Russell Boyce/Illustration
INDIA-DRUGS/ANALYSIS
RTR2ZA10
March 13, 2012
A pharmacologist works inside the bio safety room at Natco Research Centre in the southern Indian city...
Hyderabad, India
A pharmacologist works inside the bio safety room at Natco Research Centre in Hyderabad
A pharmacologist works inside the bio safety room at Natco Research Centre in the southern Indian city of Hyderabad March 13, 2012. India's move to strip German drugmaker Bayer of its exclusive rights to a cancer drug has set a precedent that could extend to other treatments, including modern HIV/AIDS drugs, in a major blow to global pharmaceutical firms, experts say. On Monday, the Indian Patent Office effectively ended Bayer's monopoly for its Nexavar drug and issued its first-ever compulsory license allowing local generic maker Natco Pharma to make and sell the drug cheaply in India. REUTERS/Krishnendu Halder (INDIA - Tags: HEALTH ANIMALS BUSINESS)
INDIA-DRUGS/ANALYSIS
RTR2ZA0Y
March 13, 2012
Pharmacologists work inside Natco Research Centre in the southern Indian city of Hyderabad March 13,...
Hyderabad, India
Pharmacologists work inside Natco Research Centre in Hyderabad
Pharmacologists work inside Natco Research Centre in the southern Indian city of Hyderabad March 13, 2012. India's move to strip German drugmaker Bayer of its exclusive rights to a cancer drug has set a precedent that could extend to other treatments, including modern HIV/AIDS drugs, in a major blow to global pharmaceutical firms, experts say. On Monday, the Indian Patent Office effectively ended Bayer's monopoly for its Nexavar drug and issued its first-ever compulsory license allowing local generic maker Natco Pharma to make and sell the drug cheaply in India. REUTERS/Krishnendu Halder (INDIA - Tags: HEALTH BUSINESS)
INDIA-DRUGS/ANALYSIS
RTR2ZA0X
March 13, 2012
A pharmacologist checks the reaction on a nude mouse after applying the SNB cytotoxic drugs for anti-tumour...
Hyderabad, India
A pharmacologist checks the reaction on a nude mouse after applying the SNB cytotoxic drugs for anti-tumour...
A pharmacologist checks the reaction on a nude mouse after applying the SNB cytotoxic drugs for anti-tumour cancer inside the bio safety cabinet at Natco Research Centre in the southern Indian city of Hyderabad March 13, 2012. India's move to strip German drugmaker Bayer of its exclusive rights to a cancer drug has set a precedent that could extend to other treatments, including modern HIV/AIDS drugs, in a major blow to global pharmaceutical firms, experts say. On Monday, the Indian Patent Office effectively ended Bayer's monopoly for its Nexavar drug and issued its first-ever compulsory license allowing local generic maker Natco Pharma to make and sell the drug cheaply in India. REUTERS/Krishnendu Halder (INDIA - Tags: HEALTH ANIMALS)
INDIA-DRUGS/ANALYSIS
RTR2ZA0R
March 13, 2012
A pharmacologist checks the reaction of cytotoxic drugs inside the containment facility at Natco Research...
Hyderabad, India
A pharmacologist checks the reaction of cytotoxic drugs inside the containment facility at Natco Research...
A pharmacologist checks the reaction of cytotoxic drugs inside the containment facility at Natco Research Centre in the southern Indian city of Hyderabad March 13, 2012. India's move to strip German drugmaker Bayer of its exclusive rights to a cancer drug has set a precedent that could extend to other treatments, including modern HIV/AIDS drugs, in a major blow to global pharmaceutical firms, experts say. On Monday, the Indian Patent Office effectively ended Bayer's monopoly for its Nexavar drug and issued its first-ever compulsory license allowing local generic maker Natco Pharma to make and sell the drug cheaply in India. REUTERS/Krishnendu Halder (INDIA - Tags: HEALTH BUSINESS)
INDIA-DRUGS/ANALYSIS
RTR2ZA0K
March 13, 2012
A pharmacologist checks the reaction on a nude mouse after applying the SNB cytotoxic drugs for anti-tumour...
Hyderabad, India
A pharmacologist checks the reaction on a nude mouse after applying the SNB cytotoxic drugs for anti-tumour...
A pharmacologist checks the reaction on a nude mouse after applying the SNB cytotoxic drugs for anti-tumour cancer inside the bio safety cabinet at Natco Research Centre in the southern Indian city of Hyderabad March 13, 2012. India's move to strip German drugmaker Bayer of its exclusive rights to a cancer drug has set a precedent that could extend to other treatments, including modern HIV/AIDS drugs, in a major blow to global pharmaceutical firms, experts say. On Monday, the Indian Patent Office effectively ended Bayer's monopoly for its Nexavar drug and issued its first-ever compulsory license allowing local generic maker Natco Pharma to make and sell the drug cheaply in India. REUTERS/Krishnendu Halder (INDIA - Tags: ANIMALS BUSINESS HEALTH)
INDIA-DRUGS/ANALYSIS
RTR2ZA0J
March 13, 2012
A pharmacologist checks the reaction on a nude mouse after applying the SNB cytotoxic drugs for anti-tumour...
Hyderabad, India
A pharmacologist checks the reaction on a nude mouse after applying the SNB cytotoxic drugs for anti-tumour...
A pharmacologist checks the reaction on a nude mouse after applying the SNB cytotoxic drugs for anti-tumour cancer inside the bio safety cabinet at Natco Research Centre in the southern Indian city of Hyderabad March 13, 2012. India's move to strip German drugmaker Bayer of its exclusive rights to a cancer drug has set a precedent that could extend to other treatments, including modern HIV/AIDS drugs, in a major blow to global pharmaceutical firms, experts say. On Monday, the Indian Patent Office effectively ended Bayer's monopoly for its Nexavar drug and issued its first-ever compulsory license allowing local generic maker Natco Pharma to make and sell the drug cheaply in India. REUTERS/Krishnendu Halder (INDIA - Tags: HEALTH ANIMALS BUSINESS)
AFGHANISTAN/
RTXRVMK
December 15, 2009
A pharmacologist shows packs of condoms at a pharmacy in Herat December 15, 2009. REUTERS/Morteza Nikoubazl...
Herat, Afghanistan
A pharmacologist shows packs of condoms at a pharmacy in Herat
A pharmacologist shows packs of condoms at a pharmacy in Herat December 15, 2009. REUTERS/Morteza Nikoubazl (AFGHANISTAN - Tags: HEALTH SOCIETY)
HEALTH
RTXQDXM
November 05, 2009
A rat genome gene chip is shown to the media by Karol Thompson, Lead Pharmacologist in the Molecular...
Silver Spring, UNITED STATES
A rat genome gene chip is shown in the Molecular Toxicology lab at the FDA near Washington
A rat genome gene chip is shown to the media by Karol Thompson, Lead Pharmacologist in the Molecular Toxicology lab at the U.S. Food and Drug Administration (FDA) headquarters in Silver Spring, Maryland, November 5, 2009. Watching on is biologist Barry Rosenzweig. REUTERS/Jason Reed (UNITED STATES HEALTH SCI TECH)
HEALTH
RTXQDXF
November 05, 2009
Jun Zhang, Toxicologic Pathologist/Pharmacologist at the U.S. Food and Drug Administration (FDA), speaks...
Silver Spring, UNITED STATES
Toxicologic Pathologist Jun Zhang speaks to the media alongside a digital scan of a kidney at the FDA...
Jun Zhang, Toxicologic Pathologist/Pharmacologist at the U.S. Food and Drug Administration (FDA), speaks to the media alongside a digital scan of a kidney during a tour of the FDA headquarters in Silver Spring, Maryland, November 5, 2009. REUTERS/Jason Reed (UNITED STATES HEALTH SCI TECH)
Health
Health
Growing Daffodils for Pharmaceuticals and Cosmetics - 24 Apr 2007
6 PICTURES
HERCEPTIN
RTXOQDK
June 09, 2006
A pharmacologist injects a phial of concentrated Herceptin in London June 9, 2006.[Herceptin, the drug...
London, UK
A pharmacologist injects a phial of concentrated Herceptin in London June 9, 2006.[Herceptin, the dr.....
A pharmacologist injects a phial of concentrated Herceptin in London June 9, 2006.[Herceptin, the drug at the centre of protests over healthcare rationing, should be used in early breast cancer and be paid for by the NHS, the cost-effectiveness watchdog said on Friday.]
HERCEPTIN
RTXOQDG
June 09, 2006
A pharmacologist holds a pack of herceptin in London June 9, 2006. [Herceptin, the drug at the centre...
London, UK
A pharmacologist holds a pack of herceptin in London June 9, 2006. [Herceptin, the drug at the centr.....
A pharmacologist holds a pack of herceptin in London June 9, 2006. [Herceptin, the drug at the centre of protests over healthcare rationing, should be used in early breast cancer and be paid for by the NHS, the cost-effectiveness watchdog said on Friday.]
HERCEPTIN
RTXOQDF
June 09, 2006
A pharmacologist holds a phial of concentrated herceptin in London June 9, 2006. [Herceptin, the drug...
London, UK
A pharmacologist holds a phial of concentrated herceptin in London June 9, 2006. [Herceptin, the dru.....
A pharmacologist holds a phial of concentrated herceptin in London June 9, 2006. [Herceptin, the drug at the centre of protests over healthcare rationing, should be used in early breast cancer and be paid for by the NHS, the cost-effectiveness watchdog said on Friday.]
HEALTH BRITAIN HERCEPTIN
RTR1E8GD
June 09, 2006
A pharmacologist injects a phial of concentrated Herceptin in London June 9, 2006. Herceptin, the drug...
London, United Kingdom
Pharmacologist injects phial of concentrated Herceptin in London
A pharmacologist injects a phial of concentrated Herceptin in London June 9, 2006. Herceptin, the drug at the centre of protests over healthcare rationing, should be used in early breast cancer and be paid for by the state health service, Britain's cost-effectiveness watchdog said on Friday. REUTERS/Luke MacGregor (BRITAIN)
HEALTH BRITAIN HERCEPTIN
RTR1E8G6
June 09, 2006
A phial and pack of herceptin are seen in London June 9, 2006. Herceptin, the drug at the centre of protests...
London, United Kingdom
Phial and pack of Herceptin are seen in London
A phial and pack of herceptin are seen in London June 9, 2006. Herceptin, the drug at the centre of protests over healthcare rationing, should be used in early breast cancer and be paid for by the state health service, Britain's cost-effectiveness watchdog said on Friday. REUTERS/Luke MacGregor (BRITAIN)
HEALTH BRITAIN HERCEPTIN
RTR1E8FK
June 09, 2006
A pharmacologist holds a pack of herceptin in London June 9, 2006. Herceptin, the drug at the centre...
London, United Kingdom
Pharmacologist holds pack of herceptin in London
A pharmacologist holds a pack of herceptin in London June 9, 2006. Herceptin, the drug at the centre of protests over healthcare rationing, should be used in early breast cancer and be paid for by the NHS, the cost-effectiveness watchdog said on Friday. REUTERS/Luke MacGregor (BRITAIN)
HEALTH BRITAIN HERCEPTIN
RTR1E8FF
June 09, 2006
A pharmacologist injects a phial of concentrated herceptin with water to dilute for use, in London June...
London, United Kingdom
Pharmacologist injects phial of concentrated herceptin with water to dilute for use in London
A pharmacologist injects a phial of concentrated herceptin with water to dilute for use, in London June 9, 2006. Herceptin, the drug at the centre of protests over healthcare rationing, should be used in early breast cancer and be paid for by the NHS, the cost-effectiveness watchdog said on Friday. REUTERS/Luke MacGregor (BRITAIN)
HEALTH BRITAIN HERCEPTIN
RTR1E8FB
June 09, 2006
A pharmacologist holds a phial of concentrated Herceptin in London June 9, 2006. Herceptin, the drug...
London, United Kingdom
Pharmacologist holds phial of concentrated herceptin in London
A pharmacologist holds a phial of concentrated Herceptin in London June 9, 2006. Herceptin, the drug at the centre of protests over healthcare rationing, should be used in early breast cancer and be paid for by the NHS, the cost-effectiveness watchdog said on Friday. REUTERS/Luke MacGregor (BRITAIN)
SHULGIN
RTXO0JF
December 02, 2005
Alexander Shulgin, pharmacologist and chemist known for his creation of new psychoactive chemicals, is...
Cambridge, USA
Alexander Shulgin, pharmacologist and chemist known for his creation of new psychoactive chemicals, .....
Alexander Shulgin, pharmacologist and chemist known for his creation of new psychoactive chemicals, is interviewed in Cambridge, Massachusetts December 1, 2005. Shulgin has synthesized and bioassayed (self-tested) hundreds of psychoactive chemicals, including MDMA, which became known as the drug Ecstasy.
SHULGIN
RTXO0JE
December 02, 2005
Alexander Shulgin (R), pharmacologist and chemist known for his creation of new psychoactive chemicals,...
Cambridge, USA
Alexander Shulgin (R), pharmacologist and chemist known for his creation of new psychoactive chemica.....
Alexander Shulgin (R), pharmacologist and chemist known for his creation of new psychoactive chemicals, and his wife Ann listen to speakers during the inaugural symposium "The Future of the Brain" at the new Picower Institute for Learning and Memory at the Massachusetts Institute of Technology in Cambridge, Massachusetts December 1, 2005. Shulgin has synthesized and bioassayed (self-tested) hundreds of psychoactive chemicals, including MDMA, which became known as the drug Ecstasy.
SHULGIN
RTXO0JD
December 02, 2005
Alexander Shulgin, pharmacologist and chemist known for his creation of new psychoactive chemicals, speaks...
Cambridge, USA
Alexander Shulgin, pharmacologist and chemist known for his creation of new psychoactive chemicals, .....
Alexander Shulgin, pharmacologist and chemist known for his creation of new psychoactive chemicals, speaks during the inaugural symposium "The Future of the Brain" at the new Picower Institute for Learning and Memory at the Massachusetts Institute of Technology in Cambridge, Massachusetts December 1, 2005. Shulgin has synthesized and bioassayed (self-tested) hundreds of psychoactive chemicals, including MDMA, which became known as the drug Ecstasy.
SHULGIN
RTXO0JC
December 02, 2005
Alexander Shulgin, pharmacologist and chemist known for his creation of new psychoactive chemicals, speaks...
Cambridge, USA
Alexander Shulgin, pharmacologist and chemist known for his creation of new psychoactive chemicals, .....
Alexander Shulgin, pharmacologist and chemist known for his creation of new psychoactive chemicals, speaks during the inaugural symposium "The Future of the Brain" at the new Picower Institute for Learning and Memory at the Massachusetts Institute of Technology in Cambridge, Massachusetts December 1, 2005. Shulgin has synthesized and bioassayed (self-tested) hundreds of psychoactive chemicals, including MDMA, which became known as the drug Ecstasy.
LIFE SHULGIN
RTR19WCC
December 01, 2005
Alexander Shulgin, pharmacologist and chemist known for his creation of new psychoactive chemicals, is...
Cambridge, UNITED STATES
Pharmacologist and chemist Shulgin is interviewed in Cambridge
Alexander Shulgin, pharmacologist and chemist known for his creation of new psychoactive chemicals, is interviewed in Cambridge, Massachusetts December 1, 2005. Shulgin has synthesized and bioassayed (self-tested) hundreds of psychoactive chemicals, including MDMA, which became known as the drug Ecstasy. REUTERS/Brian Snyder
LIFE SHULGIN
RTR19WC5
December 01, 2005
Alexander Shulgin, pharmacologist and chemist known for his creation of new psychoactive chemicals, speaks...
Cambridge, UNITED STATES
Pharmacologist and chemist Shulgin speaks at Massachusetts Institute of Technology in Cambridge
Alexander Shulgin, pharmacologist and chemist known for his creation of new psychoactive chemicals, speaks to students during the inaugural symposium "The Future of the Brain" at the new Picower Institute for Learning and Memory at the Massachusetts Institute of Technology in Cambridge, Massachusetts December 1, 2005. Shulgin has synthesized and bioassayed (self-tested) hundreds of psychoactive chemicals, including MDMA, which became known as the drug Ecstasy. REUTERS/Brian Snyder
LIFE SHULGIN
RTR19W81
December 01, 2005
Alexander Shulgin (R), pharmacologist and chemist known for his creation of new psychoactive chemicals,...
Cambridge, UNITED STATES
Pharmacologist Shulgin listens during symposium at Massachusetts Institute of Technology in Cambridge...
Alexander Shulgin (R), pharmacologist and chemist known for his creation of new psychoactive chemicals, and his wife Ann listen to speakers during the inaugural symposium "The Future of the Brain" at the new Picower Institute for Learning and Memory at the Massachusetts Institute of Technology in Cambridge, Massachusetts December 1, 2005. Shulgin has synthesized and bioassayed (self-tested) hundreds of psychoactive chemicals, including MDMA, which became known as the drug Ecstasy. REUTERS/Brian Snyder
LIFE SHULGIN
RTR19W3M
December 01, 2005
Alexander Shulgin, pharmacologist and chemist known for his creation of new psychoactive chemicals, speaks...
Cambridge, UNITED STATES
Pharmacologist and chemist Shulgin speaks at Massachusetts Institute of Technology in Cambridge
Alexander Shulgin, pharmacologist and chemist known for his creation of new psychoactive chemicals, speaks during the inaugural symposium "The Future of the Brain" at the new Picower Institute for Learning and Memory at the Massachusetts Institute of Technology in Cambridge, Massachusetts December 1, 2005. Shulgin has synthesized and bioassayed (self-tested) hundreds of psychoactive chemicals, including MDMA, which became known as the drug Ecstasy. REUTERS/Brian Snyder
LIFE SHULGIN
RTR19VXN
December 01, 2005
Alexander Shulgin, pharmacologist and chemist known for his creation of new psychoactive chemicals, speaks...
Cambridge, UNITED STATES
Pharmacologist and chemist Shulgin speaks at Massachusetts Institute of Technology in Cambridge
Alexander Shulgin, pharmacologist and chemist known for his creation of new psychoactive chemicals, speaks during the inaugural symposium "The Future of the Brain" at the new Picower Institute for Learning and Memory at the Massachusetts Institute of Technology in Cambridge, Massachusetts December 1, 2005. Shulgin has synthesized and bioassayed (self-tested) hundreds of psychoactive chemicals, including MDMA, which became known as the drug Ecstasy. REUTERS/Brian Snyder
LIFE SHULGIN
RTR19VXH
December 01, 2005
Alexander Shulgin, pharmacologist and chemist known for his creation of new psychoactive chemicals, listens...
Cambridge, UNITED STATES
Pharmacologist and chemist Shulgin is introduced during a symposium at MIT in Cambridge
Alexander Shulgin, pharmacologist and chemist known for his creation of new psychoactive chemicals, listens as he is introduced at the inaugural symposium "The Future of the Brain" at the new Picower Institute for Learning and Memory at the Massachusetts Institute of Technology in Cambridge, Massachusetts December 1, 2005. Shulgin has synthesized and bioassayed (self-tested) hundreds of psychoactive chemicals, including MDMA, which became known as the drug Ecstasy. REUTERS/Brian Snyder
FURCHGOTT
RTXHYTK
October 12, 1998
Pharmacologist Robert Furchgott, of the State University of New York in Brooklyn, speaks with reporters...
Pharmacologist Robert Furchgott, of the State University of New York in Brooklyn, speaks with report.....
Pharmacologist Robert Furchgott, of the State University of New York in Brooklyn, speaks with reporters October 12 at his home in Hewlett, New York, after it was announced that he was a joint winner of the 1998 Nobel Prize for Medicine. Furchgott shared the prize with two other American scientists for their discoveries about the role of nitric oxide as a signaling molecule in the cardiovascular system.
FURCHGOTT
RTXHYRF
October 12, 1998
Pharmacologist Robert Furchgott, of the State University of New York in Brooklyn, speaks with reporters...
New York, UNITED STATES
Pharmacologist Robert Furchgott, of the State University of New York in Brooklyn, speaks with report.....
Pharmacologist Robert Furchgott, of the State University of New York in Brooklyn, speaks with reporters at his home in Hewlett, New York October 12 after it was announced that he was a joint winner of the 1998 Nobel Prize for Medicine. [Furchgott shared the prize with two other American scientists for their discoveries about the role of nitric oxide as a signaling molecule in the cardiovascular system].
FURCHGOTT
RTXHYR5
October 12, 1998
Pharmacologist Robert Furchgott, of the State University of New York in Brooklyn, speaks with reporters...
Pharmacologist Robert Furchgott, of the State University of New York in Brooklyn, speaks with report.....
Pharmacologist Robert Furchgott, of the State University of New York in Brooklyn, speaks with reporters October 12 at his home in Hewlett, New York, after it was announced that he was a joint winner of the 1998 Nobel Prize for Medicine. [Furchgott shared the prize with two other American scientists for their discoveries about the role of nitric oxide as a signaling molecule in the cardiovascular system].
NOBEL MEDICINE FURCHGOTT
RTRI93U
October 12, 1998
Pharmacologist Robert Furchgott, of the State University of New York in Brooklyn, speaks with reporters...
New York
MEDICINE NOBEL PRIZE WINNER FURCHGOTT AT NEW YORK HOME.
Pharmacologist Robert Furchgott, of the State University of New York in Brooklyn, speaks with reporters at his home in Hewlett, New York October 12 after it was announced that he was a joint winner of the 1998 Nobel Prize for Medicine. Furchgott shared the prize with two other American scientists for their discoveries about the role of nitric oxide as a signaling molecule in the cardiovascular system.

PM/KM/JDP
RTRI935
October 12, 1998
Pharmacologist Robert Furchgott, of the State University of New York in Brooklyn, speaks with reporters...
multiple countries
NOBEL PRIZE WINNER IN MEDICINE FURCHGOTT POSES AT NEW YORK HOME.
Pharmacologist Robert Furchgott, of the State University of New York in Brooklyn, speaks with reporters October 12 at his home in Hewlett, New York, after it was announced that he was a joint winner of the 1998 Nobel Prize for Medicine. Furchgott shared the prize with two other American scientists for their discoveries about the role of nitric oxide as a signaling molecule in the cardiovascular system.

PM/ELD/ME
RTRI91T
October 12, 1998
Pharmacologist Robert Furchgott, of the State University of New York in Brooklyn, speaks with reporters...
multiple countries
NOBEL PRIZE WINNER IN MEDICINE FURCHGOTT AT NEW YORK HOME.
Pharmacologist Robert Furchgott, of the State University of New York in Brooklyn, speaks with reporters October 12 at his home in Hewlett, New York, after it was announced that he was a joint winner of the 1998 Nobel Prize for Medicine. Furchgott shared the prize with two other American scientists for their discoveries about the role of nitric oxide as a signaling molecule in the cardiovascular system.

PM/ELD/ME
Sort by
Display
Items per page
Page
of 1